In support of the proposition that AOX1 inhibition may increase the NAD+ level comes from the results of screening 304 active compounds, covering a broad range of oncology targets, to evaluate their effect on the NAD+ level in A549 lung cancer cells. The gene discussed is AOX1; the disease is lung cancer.